Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced or Metastatic Merkel Cell CarcinomaAdvanced or Metastatic Cutaneous Squamous Cell CarcinomaAdvanced or Metastatic MelanomaAdvanced or Metastatic Head and Neck Squamous Cell CarcinomaAdvanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Exicure, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT03684785
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
A Study of AST-008 in Healthy Subjects
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Exicure, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03086278
- Locations
- 🇬🇧
Richmond Pharmacology, London, United Kingdom
News
No news found